Bharat Biotech, the renowned Indian vaccine manufacturer, announced the successful completion of phase 3 trials for its oral cholera vaccine, Hillchol. The trials have confirmed the vaccine’s safety for public use, paving the way for a global launch at a time when cholera outbreaks are escalating and vaccine supply is critically short.

Developed under license from Singapore-based Hilleman Laboratories, Hillchol is poised to address a significant global shortfall in cholera vaccine availability. Bharat Biotech has set a production capacity of 200 million doses, with plans to alleviate the annual deficit of 40 million doses worldwide. The vaccine is suitable for individuals aged one year and above, making it a vital tool in the fight against cholera.

The World Health Organization (WHO) recently reported a worrying rise in cholera cases globally, with 249,793 cases and 2,137 deaths recorded in the first half of 2024 alone, across 25 countries. This marks a sharp increase from the same period in 2023, which saw 166,442 cases and 69 deaths. The demand for oral cholera vaccines has also surged, with 102 million doses requested by 17 countries since early 2023, almost double the production capacity of 51 million doses during this time.

Also Read: Siemens Healthcare Unveils Indigenous RT-PCR Kit for Rapid Monkeypox Detection

Cholera, an acute diarrhoeal disease, is primarily transmitted through the consumption of contaminated food or water. While many cases are mild or asymptomatic, severe infections can lead to acute diarrhoea and, if left untreated, can result in death within hours. The WHO emphasizes that access to clean water, proper sanitation, and hygiene are crucial measures to prevent the spread of the disease.

With the launch of Hillchol, Bharat Biotech aims to play a key role in addressing the global cholera vaccine shortage and improving public health outcomes in regions most affected by the disease.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.